-- 周四原油价格大幅上涨,此前一度跌破每桶100美元大关。 近月西德克萨斯中质原油期货合约上涨超过6%,至每桶100.11美元。布伦特原油期货合约上涨3.9%,至每桶98.41美元。 盛宝银行大宗商品策略主管奥勒·汉森指出:“停火引发的抛售潮持续时间很短,霍尔木兹海峡的通行受限持续制约供应,推动西德克萨斯中质原油和布伦特原油价格回升至每桶100美元附近。” 他补充道:“市场迅速将注意力重新集中到根本现实上:霍尔木兹海峡的通行仍然受到严重限制,全球石油系统远未恢复正常。” 据路透社报道,船舶追踪数据显示,过去24小时内,仅有一艘成品油轮和五艘干散货船通过该航道,远低于正常水平。 尽管停火已持续两周,但海峡的交通仍然几乎完全停滞。 “虽然停火为通行创造了一个窗口,但通行仍然受到条件限制和运营约束,”Kpler指出。 斯巴达商品公司研究主管尼尔·克罗斯比周四在一份报告中表示,清除海峡水雷是一项长期工作,即使在和平条件下,也至少需要四周时间。 分析人士表示,市场的快速转向表明,美伊停火带来的最初缓解被航运受限和日益紧张的外交局势所掩盖。 “伊朗通过其声明和行动明确表示,通行取决于许可、条件和政治筹码。这不是航行自由,而是胁迫,”阿联酋工业和先进技术部长兼阿布扎比国家石油公司首席执行官苏尔坦·贾比尔博士表示。 与此同时,伊朗议会议长穆罕默德·巴格尔·加利巴夫在社交媒体上表示,美国已经违反了德黑兰提出的十点框架。 加利巴夫周三在X网站上发帖称,华盛顿违反了伊朗提出的十点方案中的三项条款。 供应方面,美国能源信息署在其周报中表示,截至4月3日当周,美国原油库存增加310万桶,达到4.647亿桶。
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.